Navigation Links
Sanofi Adopts Genedata Biologics for Integrated Biopharma R&D Process Support

Basel, Switzerland (PRWEB) October 30, 2013

Genedata, a leading provider of advanced software solutions for drug discovery and life science research, today announced that Sanofi, a leading global healthcare company, has chosen Genedata Biologics as its data management platform for biologics screening activities. The first-in-class enterprise system will be used across different Sanofi research sites as a data management and workflow support platform to automate experimental data capture, increase experimental throughput, and facilitate data sharing throughout the biologics R&D process.

Out-of-the-box, Genedata Biologics supports diverse biologics R&D processes. The platform enables fully automated, high-throughput biopharmaceutical discovery and development workflows and can directly interact with laboratory instruments and robotics equipment. By increasing experimental throughput, minimizing data handling errors, and ensuring consistently high data quality standards, Genedata Biologics significantly improves efficiency in the discovery and development of novel protein-based therapeutics.

“We are delighted that Sanofi, a leading innovator in the discovery of novel biopharmaceuticals, has selected our Genedata Biologics platform,” said Dr. Othmar Pfannes, CEO of Genedata. “Our collaboration with Sanofi will drive the development of Genedata Biologics as the platform of choice for the discovery of novel biopharmaceuticals.”

About Genedata
Genedata transforms data into intelligence with a portfolio of advanced software solutions, which make research data accessible and understandable and research processes more efficient. These solutions are used worldwide by leading pharmaceutical, industrial, and agricultural biotechnology companies as well as academic research organizations. Genedata innovations enable scientific discovery that fights disease and improves health and quality of life worldwide. Founded in 1997, Genedata is headquartered in Switzerland, and has offices in Germany, Japan, and the US.

Follow us on LinkedIn.

The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

All product and service names mentioned are the trademarks of their respective companies.

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. PharmaVentures Client Sanofi Wins Scrip Outsourcing Deal of the Year Award
2. Former Sanofi-aventis and US Oncology Executive Joins New Century Health as Chief Executive Officer
3. Sanofi and Regeneron Announce Publication of Positive Phase 2 Results for Lipid-Lowering PCSK9 Antibody in The Lancet
4. Collaboration between Sanofi and Joslin Diabetes Center to focus on new drugs for diabetes
5. Sanofi Signs Agreement for Type 1 Diabetes Research with Boston Academic Teaching Hospital
6. Sanofi and Regeneron Launch Comprehensive Phase 3 Clinical Program With LDL Cholesterol-Lowering PCSK9 Antibody
7. A Look Inside, Factors of Health - Research Report on Novogen Limited, Sanofi SA, ISIS Pharmaceuticals, Inc., Amgen, Inc. and Gilead Sciences, Inc.
8. Sanofi Oncology and Colon Cancer Coalition Join Forces to Raise Awareness of Colorectal Cancer
9. U.S. FDA Grants Fast-Track Designation to Sanofi Pasteur and KaloBios Novel Biologic Candidate for Pseudomonas aeruginosa
10. Door Security at Genzyme, a Sanofi Company, Enhanced with Door Detective from Smarter Security
11. Freeslate’s Biologics Formulation System Selected by Sanofi Pasteur to Improve Efficiency of Formulation Development
Post Your Comments:
(Date:6/24/2016)... NC (PRWEB) , ... June 24, 2016 , ... Researchers ... the most commonly-identified miRNAs in people with peritoneal or pleural mesothelioma. Their findings are ... to read it now. , Diagnostic biomarkers are signposts in the blood, lung ...
(Date:6/23/2016)... June 23, 2016 /PRNewswire/ - FACIT has announced ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" ... commercialization of a portfolio of first-in-class WDR5 inhibitors ... such as WDR5 represent an exciting class of ... precision medicine for cancer patients. Substantial advances have ...
(Date:6/23/2016)... -- The Prostate Cancer Foundation (PCF) is pleased to announce 24 new ... prostate cancer. Members of the Class of 2016 were selected from a pool ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... ... 23, 2016 , ... STACS DNA Inc., the sample tracking software company, today ... Laboratory, has joined STACS DNA as a Field Application Specialist. , “I am ... and COO of STACS DNA. “In further expanding our capacity as a scientific integrator, ...
Breaking Biology Technology:
(Date:5/12/2016)... , May 12, 2016 , ... published the overview results from the Q1 wave of ... recent wave was consumers, receptivity to a program where ... with a health insurance company. "We were ... share," says Michael LaColla , CEO of Troubadour ...
(Date:5/3/2016)... Lithuania , May 3, 2016  Neurotechnology, ... released the MegaMatcher Automated Biometric Identification System ... of large-scale multi-biometric projects. MegaMatcher ABIS can process ... accuracy using any combination of fingerprint, face or ... MegaMatcher SDK and MegaMatcher Accelerator ...
(Date:4/28/2016)... Sweden , April 28, 2016 First ... M (139.9), up 966% compared with the first quarter of 2015 ... profit totaled SEK 589.1 M (loss: 18.8) and the operating margin ... 7.12 (loss: 0.32) Cash flow from operations was SEK ... The 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. ...
Breaking Biology News(10 mins):